

## Evidence for genetically determined degeneration of proprioceptive tracts in Friedreich ataxia

Marty, Brice; Naeije, Gilles; Bourguignon, Mathieu; Wens, Vincent; Jousmäki, Veikko; Lynch, David R.; Gaetz, William; Goldman, Serge; Hari, Riitta; Pandolfo, Massimo; De Tiège, Xavier

*Published in:*  
Neurology

*DOI:*  
[10.1212/WNL.0000000000007750](https://doi.org/10.1212/WNL.0000000000007750)

*Licence:*  
Other

[Link to output in Bond University research repository.](#)

### *Recommended citation(APA):*

Marty, B., Naeije, G., Bourguignon, M., Wens, V., Jousmäki, V., Lynch, D. R., Gaetz, W., Goldman, S., Hari, R., Pandolfo, M., & De Tiège, X. (2019). Evidence for genetically determined degeneration of proprioceptive tracts in Friedreich ataxia. *Neurology*, *93*(2), E116-E124. <https://doi.org/10.1212/WNL.0000000000007750>

### **General rights**

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

For more information, or if you believe that this document breaches copyright, please contact the Bond University research repository coordinator.

2 **Title: Evidence for genetically determined degeneration of proprioceptive tracts**  
3 **in Friedreich ataxia**

4  
5 **Running Title:** Corticokinematic coherence in Friedreich ataxia

6  
7 **Authors:** Brice Marty<sup>1\*</sup>, PhD & Gilles Naeije<sup>1,2\*</sup>, MD, PhD; Mathieu  
8 Bourguignon<sup>1,3,4</sup>, PhD; Vincent Wens<sup>1,5</sup>, PhD; Veikko Jousmäki<sup>6</sup>, PhD; David R  
9 Lynch<sup>7</sup>, MD, PhD; William Gaetz<sup>7</sup>, PhD; Serge Goldman<sup>1</sup>, MD, PhD; Riitta Hari<sup>8</sup>,  
10 MD, PhD; Massimo Pandolfo<sup>2</sup>, MD, PhD; Xavier De Tiège<sup>1,5</sup>, MD, PhD.

11 \*These authors equally contributed to this study.

12  
13 <sup>1</sup>Laboratoire de Cartographie fonctionnelle du Cerveau, ULB Neuroscience Institute, Université libre  
14 de Bruxelles (ULB), Brussels, Belgium.

15 <sup>2</sup>Department of Neurology, CUB Hôpital Erasme, Université libre de Bruxelles (ULB), Brussels,  
16 Belgium.

17 <sup>3</sup>Laboratoire Cognition Langage et Développement, ULB Neuroscience Institute, Université libre de  
18 Bruxelles (ULB), Brussels, Belgium.

19 <sup>4</sup>Basque Center on Cognition, Brain and Language (BCBL), Donostia, Spain.

20 <sup>5</sup>Department of Functional Neuroimaging, Service of Nuclear Medicine, CUB Hôpital Erasme,  
21 Université libre de Bruxelles (ULB), Brussels, Belgium.

22 <sup>6</sup>Department of Neuroscience and Biomedical Engineering, School of Science, Aalto University,  
23 Espoo, Finland.

24 <sup>7</sup>Children's Hospital of Philadelphia, Philadelphia, United States of America.

25 <sup>8</sup>Department of Art, Aalto University, Helsinki, Finland.

26  
27 **Corresponding author:** Dr Gilles Naeije, Laboratoire de Cartographie fonctionnelle du Cerveau, ULB  
28 Neuroscience Institute, Université libre de Bruxelles (ULB), 808 Lennik Street, 1070 Brussels,  
29 Belgium. E-mail : [Gilles.Naeije@erasme.ulb.ac.be](mailto:Gilles.Naeije@erasme.ulb.ac.be).

30  
31 **Word count:**

32 Title (characters) : 94

33 Abstract (words) : 219

34 Manuscript (words) : 3848

35

1 **Fundings:**

2 This study was financially supported by the research grant “Les Voies du Savoir”  
3 from the Fonds Erasme (Brussels, Belgium), the Fonds de la Recherche Scientifique  
4 (FRS-FNRS, Brussels, Belgium; research credit: J.0095.16.F), and a research grant  
5 from the Friedreich Ataxia Research Alliance (FARA, Drs Massimo Pandolfo,  
6 William Gaetz and David Lynch). Gilles Naeije was supported by a research grant  
7 from the Fonds Erasme (Brussels, Belgium). Mathieu Bourguignon was supported by  
8 the program Attract of Innoviris (grant 2015-BB2B-10), by the Spanish Ministry of  
9 Economy and Competitiveness (grant PSI2016-77175-P), and by the Marie  
10 Skłodowska-Curie Action of the European Commission (grant 743562). Xavier De  
11 Tiège and Gilles Naeije are Postdoctorate Clinical Master Specialist at the Fonds de la  
12 Recherche Scientifique (FRS-FNRS, Brussels, Belgium). The MEG project at the  
13 CUB Hôpital Erasme is financially supported by the Fonds Erasme (Research grant  
14 “Les Voies du Savoir”, Brussels, Belgium). Accelerometer and PAM stimulator were  
15 designed and manufactured at Aalto NeuroImaging, Aalto University, Finland

16

17 **Disclosures:**

18 Dr. Naeije reports no disclosure.  
19 Mr Marty reports no disclosure.  
20 Mr Bourguignon reports no disclosure.  
21 Mr Wens reports no disclosure.  
22 Mr Jousmäki reports no disclosure.  
23 Dr Lynch reports no disclosure.  
24 Mr Gaetz reports no disclosure.  
25 Dr Goldman reports no disclosure  
26 Dr Hari reports no disclosure.  
27 Dr Pandolfo reports no disclosure.  
28 Dr De Tiège reports no disclosure.  
29

1 **Abstract**

2 Objective: To assess using magnetoencephalography the developmental vs.  
3 progressive character of the impairment of spino-cortical proprioceptive pathways in  
4 Friedreich ataxia (FRDA).

5 Methods: Neuromagnetic signals were recorded from 16 right-handed FRDA patients  
6 (9 females, mean age: 27 y, mean scale for the assessment and rating of ataxia  
7 (SARA) score: 22.25) and matched healthy controls while they performed right finger  
8 movements either actively or passively. The coupling between movement kinematics  
9 (i.e., acceleration) and neuromagnetic signals was assessed using coherence at sensor  
10 and source levels. Such coupling, i.e., the corticokinematic coherence (CKC),  
11 specifically indexes proprioceptive afferent inputs to contralateral primary  
12 sensorimotor (cSM1) cortex. Non-parametric permutations and Spearman rank  
13 correlation test were used for statistics.

14 Results: In both groups of participants and movement conditions, significant coupling  
15 peaked at cSM1 cortex. Coherence levels were 70–75% lower in FRDA patients than  
16 in healthy controls in both movement conditions. In FRDA patients, coherence levels  
17 correlated with genotype alteration (i.e., the size of GAA1 triplet expansion) and the  
18 age of symptoms onset, but not with disease duration nor with SARA.

19 Conclusion: This study provides electrophysiological evidence demonstrating that  
20 proprioceptive impairment in FRDA is mostly genetically determined and scarcely  
21 progressive after symptoms onset. It also positions CKC as a reliable, robust and  
22 specific marker of proprioceptive impairment in FRDA.

23

24 **Keywords:** Friedreich ataxia, proprioception, cerebellum, magnetoencephalography,  
25 corticokinematic coherence.

## 1 **Introduction**

2           Friedreich ataxia (FRDA) is a rare autosomal recessive inherited ataxia mainly  
3 caused by expanded GAA triplet repeats in the first intron of the frataxin (FXN) gene  
4 (GAA1). GAA1 triplet expansion size correlates with age of onset and disease  
5 severity.<sup>1</sup> FRDA neuropathology affects dorsal root ganglia (DRG), posterior columns  
6 and spinocerebellar tracts in the spinal cord, followed by progressive atrophy of the  
7 cerebellar dentate nuclei and efferent fibers<sup>2</sup>, leading to a “tabeto-cerebellar” ataxic  
8 pattern.<sup>3</sup>

9           Neuropathology and imaging studies show that DRG and spinal abnormalities  
10 occur very early and seem stable along time, leading to the onset and initial  
11 progression of ataxia.<sup>4,5</sup> However, DRG from patients with long disease duration still  
12 show signs of active inflammation, supporting a continuing degenerative process.<sup>5</sup>  
13 Dissecting the developmental from the progressive components of DRG and spinal  
14 pathology is therefore a critical issue for translational research in FRDA.<sup>6</sup>

15           Here, we used magnetoencephalography (MEG) and corticokinematic  
16 coherence (CKC) to answer that issue by objectively assessing the function of  
17 proprioceptive ascending pathways in FRDA. CKC indexes the coupling between  
18 cortical activity and movement kinematics (e.g., acceleration) during repetitive  
19 voluntary<sup>7,8</sup> and passive<sup>9,10</sup> movements. CKC is driven by movement-related  
20 proprioceptive afferents to contralateral primary sensorimotor (cSM1) cortex<sup>10,11</sup> and  
21 is relatively independent of movement rate.<sup>12</sup> Typically, CKC peaks at movement  
22 frequency and harmonics over cSM1 cortex.<sup>7-10</sup> We expected CKC levels at cSM1  
23 cortex to be substantially reduced in FRDA patients and that they would correlate  
24 either with GAA1 triplet expansion size, age of disease onset, clinical scores, or  
25 disease duration.

1     **Materials and methods**

2     ***Participants***

3             Sixteen FRDA patients (mean age 27 y, range 9–46 y; 9 females and 7 males;  
4     mean scale for the assessment and rating of ataxia (SARA) score: 21.4, range 9.5–  
5     30.5; mean GAA1 triplet expansion: 670, range 280–1000) and sixteen healthy  
6     controls (mean age 29 y; range 10–53 y; 9 females) without history of  
7     neuropsychiatric disease contributed to the study. Of note, one patient was  
8     heterozygous for a GAA1 repeat expansion and had a point mutation in the FXN  
9     gene.

10            Nine FRDA patients (mean age 36 y, range 23–46 y; 5 females; mean SARA  
11     score: 24, range 15.5–30.5, mean GAA1 triplet expansion: 621, range 280–910) also  
12     accepted to undergo somatosensory evoked potential (SEP) recording using electrical  
13     stimulation of the right median nerve. Recording and analysis of SEPs were done as  
14     in Santoro et al.<sup>13</sup> except that, for comfort reasons, the two trials consisted of 256  
15     rather than 1000 epochs.

16

17     ***Ethical statement***

18            All participants were included in the study after written informed consent. The  
19     study had prior approval by the CUB Hôpital Erasme Ethics Committee and was  
20     performed in accordance with the Declaration of Helsinki.

21

22

23     ***Experimental paradigm***

24            The MEG experiment comprised three 5-min conditions (*Active*, *Passive*, and  
25     *Rest*) that were randomized across participants.

1           Figure 1 illustrates the two movement conditions used in this study.

2           In *Active*, participants performed repetitive right index finger–thumb  
3 oppositions at a regular rate (about 2 Hz). Pauses were introduced if necessary.

4           In *Passive*, a pneumatic artificial muscle (PAM) stimulator adapted from  
5 Piitulainen et al.<sup>11</sup> induced passive flexion–extensions of participants’ right index  
6 finger at 3 Hz. This stimulator consisted of an elastic PAM (DMSP-10-100 AM-CM,  
7 Festo AG & Co, Esslingen, Germany) inserted horizontally in a  
8 polyoxymethylene cylinder on which participants could rest their hand. The PAM  
9 moved in the horizontal direction (5 mm of displacement) when its internal air  
10 pressure was varied (0–4 bar). The pressure was regulated by a solenoid valve  
11 (SY5220-6LOU-01F-Q, SMC Corporation, Tokyo, Japan) that was controlled by the  
12 internal MEG-stimulator system.

13           In *Active* and *Passive* conditions, participants’ finger movements were  
14 monitored with a 3-axis accelerometer (Acc, ADXL335 iMEMS Accelerometer,  
15 Analog Devices, Inc., Norwood, MA, USA) attached to the nail of their right index  
16 finger.

17           In *Rest*, participants were instructed to relax and not to move.

18           In all conditions, participants were instructed to gaze at a fixation point in the  
19 magnetically shielded room (MSR) to avoid any eye movements or visual perception  
20 of the moving finger. They also wore earplugs to block the noise generated by finger  
21 movements or the PAM stimulator.

22

23           — Place Figure 1 about here —

24

25

1 ***Data acquisition***

2 MEG signals were recorded with a whole-scalp-covering neuromagnetometer  
3 placed in a light-weight MSR (Vectorview & Maxshield™ (Elekta Oy, Helsinki,  
4 Finland) for 10 patients and 4 control individuals, and its upgraded version with  
5 similar sensor layout, the Triux & Maxshield™ (MEGIN, Helsinki, Finland), for 6  
6 patients and 12 control individuals). MEG signals were filtered at 0.1–330 Hz and  
7 sampled at 1 kHz. Four head-tracking coils were used to monitor participants' head  
8 position inside the MEG helmet. The locations of the coils and at least 200 head-  
9 surface points (on scalp, nose, and face) with respect to anatomical fiducials were  
10 determined with an electromagnetic tracker (Fastrak, Polhemus, Colchester, VT,  
11 USA) prior to MEG data acquisition. Acc signals were recorded time-locked to MEG  
12 using a lowpass at 330 Hz and a sampling rate of 1 kHz. High-resolution 3D-T1  
13 cerebral magnetic resonance images (MRIs) were acquired on a 1.5 T MRI scanner  
14 (Intera, Philips, The Netherlands). Both MEG and MRI data were acquired at the  
15 CUB Hôpital Erasme.

16

17 ***Data preprocessing***

18 Continuous MEG data were first preprocessed off-line using the signal space  
19 separation method<sup>14</sup> to suppress external interferences and correct for head  
20 movements. Acceleration signal was computed at every time sample as the Euclidian  
21 norm of the three band-passed Acc channels. Both MEG and Acc signals were split  
22 into 2-s epochs with 1.5-s overlap, leading to a spectral resolution of 0.5 Hz.<sup>15</sup> Epochs  
23 within which the amplitude of MEG signals filtered through 0.1–145 Hz exceeded 3  
24 pT (magnetometers) or 0.7 pT/cm (gradiometers) were marked as artifact-  
25 contaminated and rejected from further analysis. This procedure led to a similar



1 amount of epochs (FRDA patients: *Active*  $665 \pm 126$  (mean  $\pm$  SD), *Passive*  $667 \pm$   
2  $160$ ; healthy controls: *Active*  $755 \pm 52$ , *Passive*  $655 \pm 180$ ) between conditions  
3 (ANOVA, *Active* vs. *Passive*;  $F_{1,15} = 1.09$ ,  $p = 0.44$ ) and groups of participants  
4 (ANOVA, FRDA patients vs. healthy controls  $F_{2,30} = 1.38$ ,  $p = 0.26$ ) .

5

### 6 ***Movement regularity***

7 Movement regularity was quantified in the *Active* condition for all participants.  
8 The principal component of the three high-passed (0.5 Hz) Acc signals was computed  
9 and then Fourier transformed. The resulting power spectrum was then smoothed with  
10 a Gaussian kernel (full width at half maximum (FWHM) 0.3 Hz). The first peak of the  
11 spectrum curve was then identified and its FWHM was estimated. The former  
12 provided an estimate of movement frequency, and the latter, an indicator of  
13 movement regularity (i.e., the smaller its value, the more regular the movements), at  
14 least under the hypothesis of movement stationarity. However, self-paced movement  
15 may present nonstationary drifts in movement frequency over the whole recording  
16 session while still being regular on the short term. Therefore, the global regularity  
17 index may lead to a false indication of irregularity. To take this possibility into  
18 account, we also estimated a “short-time measure” of regularity by computing the  
19 above FWHM index within 10 s-wide sliding windows and then averaging it over all  
20 windows.

21

### 22 ***Coherence analyses between Acc and MEG signals in sensor space***

23 Coherence quantifies the degree of coupling between two signals by providing a  
24 number between 0 (no linear dependency) and 1 (perfect linear dependency) for each  
25 frequency.<sup>16</sup> For each movement condition (*Active*, *Passive*), coherence between Acc

1 and MEG signals was computed in sensor space as in <sup>7,10,17</sup> to identify, without any *a*  
2 *priori*, the frequencies showing significant coupling between those signals.  
3 Frequencies showing consistent coherence across participants in sensor space were  
4 then defined as *frequencies of interest* for source-level analyses.

5

### 6 ***Coherence analyses in source space***

7 MEG forward models and individual-level coherence maps were then computed  
8 in source space following a procedure detailed in previous studies from our  
9 group<sup>35,38,39</sup> to obtain normalized coherence maps in the MNI space for each  
10 participant, condition (*Active, Passive*), and frequency of interest. Coherence maps at  
11 the group level were subsequently produced.<sup>35,38,39</sup>

12

### 13 ***Statistical analyses***

#### 14 ***Sensor-space coherence at individual level***

15 The statistical significance of individual coherence levels was assessed under  
16 the hypothesis of linear independence.<sup>16</sup> The significance threshold (*Ct*) is given by

$$17 \quad Ct = 1 - p^{1/(L-1)}$$

18 where *p* is the chosen significance level for individual channels and *L*, the number of  
19 disjoint epochs used for coherence estimation. The significance level was set to *p* <  
20 0.05 Bonferroni corrected for multiple comparisons (i.e., 306 channels).

21

#### 22 ***Statistical differences in movement frequency, movement regularity and coherence*** 23 ***levels in sensor space***

24 Differences in movement frequency (*Active, Passive*) and regularity (*Active*)  
25 between groups of participants (FRDA patients vs. healthy controls) were assessed

1 using a 2-sample *t*-test. The effects of group of participants, movement conditions,  
2 and frequencies of interest on maximal sensor-level coherence were assessed with 3-  
3 way repeated-measures ANOVA. Results were considered statistically significant at *p*  
4 < 0.05.

5

#### 6 *Source-space coherence at the group level*

7 Statistical significance of local coherence maxima, identified in group-level  
8 coherence maps for each movement condition and frequency of interest, was assessed  
9 with a non-parametric permutation test<sup>18</sup>, following the procedure described in<sup>7</sup>.  
10 Statistical differences in group-level coherence maps in *Active* and *Passive* between  
11 healthy controls and FRDA patients were assessed for each frequency of interest with  
12 a similar non-parametric permutation test as those previously described<sup>7</sup>, with the  
13 only difference that group-level difference maps were obtained by subtracting healthy  
14 controls' Fisher-transformed *Active* or *Passive* coherence maps with the  
15 corresponding FRDA patients' coherence maps.

16

#### 17 *Correlation analyses of individual source-space coherence values*

18 Spearman rank correlation tests were used to seek for possible relations between  
19 FRDA patients' maximum coherence levels at cSM1 cortex for each frequency of  
20 interest and the size of GAA1 triplet expansion, SARA score, age of onset of clinical  
21 symptoms, and disease duration. Of note, the patient with point mutation in the FXN  
22 gene was excluded from the correlations with GAA1 triplet expansion. Results were  
23 considered statistically significant at *p* < 0.05.

24

25

1 ***Data availability statement***

2 De-identified participants' data will be shared as well as study protocol and  
3 statistical analyses upon request.

4

5 **Results**

6 ***Active condition***

7 Despite identical instructions, FRDA patients moved at a slower pace and less  
8 regularly than healthy controls (movement frequency (F0):  $1.75 \pm 0.5$  Hz vs.  $2.60 \pm 1$   
9 Hz,  $p = 0.03$ ; stationary movement regularity:  $1.20 \pm 1.10$  Hz vs  $0.64 \pm 0.35$  Hz,  $p =$   
10  $0.084$ ; short-time regularity:  $0.59 \pm 0.14$  Hz vs  $0.49 \pm 0.07$  Hz;  $p = 0.016$ ).

11

12 ***Coherence at the sensor level***

13 Table 1 and Figure 2 summarize sensor-level coherence results obtained in both  
14 groups of participants and movement conditions.

15 Statistically significant coherence peaked at F0 and its first harmonics (F1) in  
16 all healthy controls in the *Active* condition, and in all (F0) and 15/16 (F1) of them in  
17 the *Passive* condition. All FRDA patients displayed a significant coherence peak at  
18 F0, while 15/16 of them presented a significant coherence peak at F1 in the *Active*  
19 condition. In the *Passive* condition, significant coherence was found in 14/16 of  
20 FRDA patients at F0 and in 8/16 of them at F1. In both groups of participants and  
21 conditions, coherence was maximal at central sensors contralateral to hand  
22 movements.

23

24 — Place Table 1 about here —

25

1           The 3-way ANOVA conducted on maximal sensor level coherence disclosed a  
2 main effect of frequency of interest ( $F_{1,15} = 17.2, p = 0.001$ ), movement condition  
3 ( $F_{1,15} = 27.2, p = 0.0001$ ), and participants' group ( $F_{1,15} = 20.3, p < 0.0001$ ), and an  
4 interaction between frequency of interest and movement condition ( $F_{1,15} = 10.5, p =$   
5  $0.006$ ) and no other significant interaction ( $F_{1,15} < 0.70, p > 0.77$ ). This pattern of  
6 results was explained by higher CKC values in healthy controls compared with FRDA  
7 patients, and lower CKC values at F1 than at F0 in *Passive*. Based on sensor-level  
8 coherence results, only F0 and F1 were considered for further source-space analyses.

9

10 — Place Figure 2 about here —

11

## 12 ***Coherence at the source level***

13           To identify the neuronal networks involved in coherence in *Active* and *Passive*  
14 conditions, similar coherence analyses were performed at the frequencies of interest  
15 (i.e., F0 and F1) at the source level. Figure 3 illustrates the results.

16

### 17 ***Active condition***

18           In healthy controls, significant F0 and F1 coherence occurred at cSM1 cortex  
19 with maximal amplitude over the hemisphere contralateral to hand movements (F0,  
20 MNI peak coordinates:  $[-44 -21 58]$  mm, coherence value: 0.40; F1,  $[-43 -23 60]$ ,  
21 0.38). Of note, a clear but non-significant local coherence maximum was also  
22 observed at the ipsilateral SM1 (iSM1) cortex ( $[42 -31 56]$ , 0.10). In FRDA patients,  
23 significant F0 coherence occurred at bilateral SM1 cortices with maximal amplitude  
24 over the hemisphere contralateral to hand movements (cSM1 cortex,  $[-41 -18 60]$ ,  
25 0.10; iSM1 cortex,  $[34 -18 65]$ , 0.08). Significant F1 coherence was also only found

1 at cSM1 cortex ([-45 -22 57], 0.10). Coherence at F0 and F1 over cSM1 cortex (F0,  
2 [-48 -29 56]; F1, [-36 -17 64]) was significantly higher in healthy controls than  
3 FRDA patients (F0: 0.4 vs 0.10; F1: 0.38 vs ??0.08??).

4

#### 5 *Passive condition*

6 In healthy controls and FRDA patients, significant F0 and F1 coherence  
7 occurred at cSM1 cortex (healthy controls, F0: [-45 -21 58], 0.3/F1: [-47 -25 57],  
8 0.10; FRDA patients, F0: [-48 -19 54], 0.10/F1: [-49 -20 51], 0.04). At F0,  
9 coherence levels at cSM1 cortex were significantly lower in FRDA patients compared  
10 with healthy controls (F0: [-33 -14 68], 0.10 vs 0.30), while no significant difference  
11 was observed at F1.

12

13 — Place Figure 3 about here —

14

#### 15 *Correlation analyses*

16 In FRDA patients with GAA1 triplet expansion (15/16 FRDA patients), levels  
17 of cSM1 cortex coherence in *Active* F1 correlated with the age of onset ( $r = 0.75, p =$   
18  $0.004$ ) and with the size of GAA1 triplet expansion ( $n = 15; r = -0.67, p = 0.001$ ). In  
19 *Passive*, levels of F1 cSM1 cortex coherence correlated only with the size of GAA1  
20 triplet expansion ( $n = 15; r = -0.59, p = 0.009$ ). No other correlation appeared  
21 significant. Figure 4 illustrates those correlations.

22

23 — Place Figure 4 about here —

24

25

1 **SEPs**

2 N20 response was clearly identified in only 2/9 of the FRDA patients who  
3 underwent classical SEP testing, with latencies of 26.1 ms and 27.7 ms, and  
4 amplitudes of 0.3  $\mu$ V and 0.4  $\mu$ V (normal values of the Clinical Neurophysiology  
5 Department of the CUB Hôpital Erasme for N20 latency and amplitude:  $19.6 \pm 1.0$  ms  
6 and  $2.1 \pm 0.9$   $\mu$ V respectively).

7

8

9 **Discussion**

10 This study demonstrates that (i) the coupling between index-finger movement  
11 kinematics and cSM1 cortex neuromagnetic activity is reduced in FRDA patients  
12 compared with healthy controls matched for age and sex during both active and  
13 passive finger movements, (ii) CKC is a more reliable measure than SEPs in FRDA  
14 patients, and (iii) the level of coherence at cSM1 cortex in FRDA patients correlates  
15 with the size of GAA1 triplet expansion in both *Active* and *Passive* at F1, but not with  
16 the SARA score or disease duration. These findings provide empirical evidence  
17 supporting that the severity of spino-cortical proprioceptive pathways degeneration in  
18 FRDA is genetically determined and has little tendency to progress after disease  
19 onset. They also validate CKC as a specific and robust electrophysiological marker of  
20 spino-cortical proprioceptive pathways degeneration in FRDA.

21 Previous CKC studies performed in healthy controls demonstrated that CKC is  
22 robustly observed at cSM1 cortex at the individual level during both active<sup>7,8,17</sup> and  
23 passive<sup>10,11</sup> finger movements. Furthermore, they highlighted that CKC is driven by  
24 movement-related proprioceptive afferent input to cSM1 cortex with negligible  
25 influence of tactile input.<sup>10,11</sup> A longitudinal study performed in a similar population

1 also demonstrated that CKC levels at cSM1 cortex are fairly reproducible across  
2 sessions.<sup>19</sup> All these findings set the rationale for using CKC to obtain an objective,  
3 reliable, and specific measure of proprioceptive pathways impairment in FRDA  
4 patients. The working hypothesis guiding the present study was that the use of CKC  
5 would bring novel insights into FRDA pathophysiology and, more particularly, into  
6 the developmental vs. the degenerative character of proprioceptive pathways  
7 impairment in this disorder.

8 As expected, in both *Active* and *Passive* conditions, CKC levels were  
9 substantially decreased in FRDA patients (decrease by about a third or a quarter of the  
10 values in healthy controls). Furthermore, a negative correlation was found in both  
11 movement conditions between CKC levels at F1 and the size of GAA1 triplet  
12 expansion. These findings therefore imply that the low CKC levels observed in FRDA  
13 patients are actually the consequence of an early and scarcely progressive, possibly  
14 developmental, pathology of spino-cortical proprioceptive pathways. These results  
15 also imply that whenever genetic therapy to restore DRG and medullary posterior  
16 columns FXN level becomes available, it should be started as early as possible at the  
17 preclinical stage. Yet, an early proprioceptive pathology, possibly even hypoplasia,  
18 does not imply that the remaining somatosensory neurons responsible for residual  
19 proprioception in FRDA patients would not degenerate with time and contribute to  
20 the progressive worsening of ataxia. However, CKC data indicate that, in the course  
21 of FRDA, the ongoing loss of proprioception is likely to be minor compared with  
22 cerebellar and pyramidal degenerations.<sup>2,20</sup> Longitudinal CKC investigations along  
23 the course of FRDA could help to clarify the existence of subtle progressive  
24 dysfunction of the posterior column and to assess the potential yield of early  
25 therapeutic intervention to alleviate symptoms of the proprioceptive impairment. Still,



1 the lack of correlation of CKC levels at cSM1 cortex and disease duration does not  
2 support this hypothesis.

3 Previous studies have demonstrated that SEPs are not reliably identified  
4 between 1/3 and 2/3 of FRDA patients.<sup>13,21–26</sup> Our finding that SEPs were visible only  
5 in 2/9 FRDA patients is in line with those data. In the Naples cohort<sup>15</sup> where SEPs  
6 were detectable in 36 out of 52 patients, FRDA patients had similar GAA1 repeat  
7 expansions ( $621 \pm 225$  for CUB Hôpital Erasme vs.  $661 \pm 257$  for Naples) but  
8 different disease durations ( $20 \pm 11$  years vs.  $10 \pm 7$  years). However, the difference  
9 in disease duration is not likely to account for the discrepancy between our rates of  
10 recordable SEPs as, in the Naples cohort, N20 amplitude did not correlate with  
11 disease duration. A possible explanation for the better sensitivity of SEPs in the  
12 Naples cohort could be that, to record SEPs, they averaged the neural responses  
13 elicited by 2000 electrical stimuli on each side<sup>15</sup>, while we limited the number of  
14 electrical stimuli on each side to 512 meaning that their signal-to-noise ratio was 2  
15 times ours. Still, despite the frequent absence of SEPs in FRDA patients, CKC was  
16 reliably recorded in all (*Active*) or almost all (*Passive*) patients, even when SEPs were  
17 not detectable. Interestingly, when measurable, the amplitude of N20 responses  
18 obtained in previous studies tended to be stable over time and correlated with the size  
19 of GAA1 triplet expansion, while the correlation with disease progression varied  
20 across studies.<sup>13,22–25,27</sup> These findings indicate that the loss of N20 and the reduction  
21 of CKC levels share similar disease-related impairment of the somatosensory system.  
22 However, as CKC can be measured in almost all FRDA patients, it appears as a  
23 robust, more reliable and specific marker than SEP recordings to assess the pathology  
24 of proprioceptive pathways in FRDA. FRDA patients who are compound  
25 heterozygotes (GAA expansion and a *FXN* point mutation) display the same mixed

1 afferent and cerebellar ataxia phenotype than homozygous GAA triplet expansion  
2 FRDA patients<sup>28</sup>, so CKC can be used to assess spino-cortical proprioceptive  
3 pathways alteration in these patients as well. Results also suggest that CKC could be  
4 of great interest to assess impairment of proprioceptive pathways in various diseases  
5 affecting the posterior columns of the spinal cord, such as multiple sclerosis<sup>29</sup>,  
6 vitamin B12 deficiency<sup>30</sup>, stroke<sup>31</sup>, and medullary compression.<sup>32</sup> Such studies would  
7 also inform about the specificity of the CKC alterations in different patient groups,  
8 including FRDA. Finally, in FRDA and other genetic spinocerebellar ataxias (SCAs),  
9 CKC could potentially serve to identify preclinical stages in patients in whom a  
10 genetic diagnosis was made. Indeed, in most common SCAs (1, 2, 3 & 6) and in  
11 FRDA, genotypic anomalies only predict a part of age-of-onset variability, disease  
12 severity, and survival.<sup>33,35</sup> On the other hand, in SCAs, SEPs are altered as early as  
13 eight years before symptoms onset (for a review, see<sup>36</sup>), which suggests that CKC, as  
14 a robust method, might help to sort pre-symptomatic patients and therefore play a role  
15 in the determination of the optimum time for early therapeutic intervention.

16 That FRDA patients moved at a slower pace and less regularly than healthy  
17 controls in the *Active* condition is unlikely to explain the difference in CKC levels  
18 observed between the two groups. Indeed, CKC levels in *Active* and *Passive*  
19 conditions were similar at F0 in both groups of participants and stronger in the *Active*  
20 condition at F1 in FRDA patients. This (expectable) difference in movement  
21 characteristics between FRDA patients and healthy controls justifies the importance  
22 of the *Passive* condition. The interest of the use of a metronome to pace active  
23 movements should be addressed in future studies. In *Active* and *Passive* conditions,  
24 CKC peaked at F0 and F1 over cSM1 cortex in both groups of participants, which is  
25 in line with previous CKC studies performed in healthy individuals.<sup>7,9,10</sup> Our finding

1 that, in the *Active* condition, local CKC maxima at iSM1 cortex were significant only  
2 in FRDA patients is explained by the statistical approach used in this study. Indeed,  
3 permutation tests may be too conservative (type II error) for voxels other than those  
4 with high coherence levels.<sup>18</sup> In FRDA patients, CKC levels at cSM1 cortex were  
5 much lower than those observed in healthy controls, explaining why CKC levels at  
6 iSM1 cortex appeared significant in FRDA patients and not in healthy controls.

7         The neural bases of CKC at F0 and F1 are still debated. F0 and F1 CKC may  
8 either reflect cortical processing of different movement kinematics features, or F1  
9 may be due to non-sinusoidal cortical activity at F0, leading to coherence at twice  
10 F0.<sup>7</sup> In repetitive index-finger movements, such as those used in this study, F0 is  
11 likely to reflect cycles of index finger flexions/extensions and corresponding  
12 proprioceptive signals, while F1 might reflect the contraction/relaxation of agonist  
13 and antagonist muscles during both flexion and extension. This difference between F0  
14 and F1 CKC might explain why FRDA patients' CKC levels at cSM1 cortex  
15 correlated with the size of GAA1 triplet expansion and the age of onset better at F1  
16 than at F0. Also, the absence of significant difference between healthy controls and  
17 FRDA patients at F1 in the *Passive* condition are probably related to the relatively  
18 weak coherence at F1 observed in healthy controls and to the variability of this  
19 frequency in FRDA patients.

20         In conclusion, FRDA is a complex neurogenetic disorder that mainly involves  
21 degeneration of proprioceptive afferent and cerebellar pathways. Clinical rating scales  
22 are able to capture the progression of cerebellar impairment, but the involvement of  
23 proprioceptive pathways is less well quantified clinically, hence the need for robust  
24 markers of proprioceptive impairment. We provided electrophysiological evidence  
25 that spino-cortical proprioceptive impairment in FRDA is mostly genetically

1 determined and scarcely progressive after symptoms onset. We also demonstrate that  
 2 CKC represents a reliable and robust individual-level marker of spino-cortical  
 3 proprioceptive loss in FRDA. CKC may therefore represent a useful addition to the  
 4 armamentarium of FRDA clinical evaluation to assess the natural history of this  
 5 disorder and the efficacy of dedicated early therapeutic approaches.

6  
 7

8 **Appendix 1**

9

Name	Location	Role	Contribution
Gilles Naeije, MD, PhD	Université libre de Bruxelles (ULB), Brussels, Belgium	Author	Designed and conceptualized study; conducted the experiments; analyzed the data; wrote the manuscript; designed Figure 4; wrote the revisions.
Brice Marty, PhD	Université libre de Bruxelles (ULB), Brussels, Belgium	Author	Conducted the experiments; analyzed the data; contributed to the writing of Methods, Results, and Figures 1-3 legends; designed Figures 1-3.
Mathieu Bourguignon, PhD	Université libre de Bruxelles (ULB), Brussels, Belgium	Author	Analyzed the data; drafted the manuscript for intellectual content.
Vincent Wens, PhD	Université libre de Bruxelles (ULB), Brussels, Belgium	Author	Analyzed the data; drafted the manuscript for intellectual content.
Veikko Jousmäki, PhD	School of Science, Aalto University, Espoo, Finland	Author	Designed and provided the PAM stimulator; provided input for research design and interpretation; drafted the manuscript for intellectual content.
David R Lynch, MD, PhD	Children’s Hospital of Philadelphia, Philadelphia, USA	Author	Drafted the manuscript for intellectual content.
William Gaetz, PhD	Children’s Hospital of Philadelphia, Philadelphia,	Author	Provided input for research design and interpretation; drafted the

	USA		manuscript for intellectual content.
Serge Goldman, MD, PhD	Université libre de Bruxelles (ULB), Brussels, Belgium	Author	Drafted the manuscript for intellectual content; provided input for research design and interpretation.
Riitta Hari, MD, PhD	Department of Art, Aalto University, Helsinki, Finland	Author	Drafted the manuscript for intellectual content; provided input for research design and interpretation.
Massimo Pandolfo, MD, PhD	Université libre de Bruxelles (ULB), Brussels, Belgium	Author	Designed and conceptualized the study; drafted the manuscript for intellectual content; provided input for research design and interpretation.
Xavier De Tiège, MD, PhD	Université libre de Bruxelles (ULB), Brussels, Belgium	Author	Designed and conceptualized the study; wrote the manuscript; drafted the manuscript for intellectual content; provided input for research design and interpretation; contributed to the revisions.

1

## 2 **References**

- 3 1. Campuzano V, Montermini L, Molto MD, et al. Friedreich's ataxia: autosomal  
4 recessive disease caused by an intronic GAA triplet repeat expansion. *Science*.  
5 1996;271(5254):1423-1427.
- 6 2. Koeppen AH, Mazurkiewicz JE. Friedreich Ataxia: Neuropathology Revised. *J*  
7 *Neuropathol Exp Neurol*. 2013;72(2):78-90.  
8 doi:10.1097/nen.0b013e31827e5762
- 9 3. Pandolfo M. Friedreich Ataxia. *Arch Neurol*. 2008;65(10).  
10 doi:10.1001/archneur.65.10.1296
- 11 4. Mascalchi M, Bianchi A, Ciulli S, et al. Lower medulla hypoplasia in  
12 Friedreich ataxia: MR Imaging confirmation 140 years later. *J Neurol*.  
13 2017;264(7):1526-1528. doi:10.1007/s00415-017-8542-8
- 14 5. Koeppen AH, Ramirez RL, Becker AB, Mazurkiewicz JE. Dorsal root ganglia

- 1 in Friedreich ataxia: satellite cell proliferation and inflammation. *Acta*  
2 *Neuropathol Commun.* 2016;4(1):46. doi:10.1186/s40478-016-0288-5
- 3 6. Piguet F, de Montigny C, Vaucamps N, Reutenauer L, Eisenmann A, Puccio H.  
4 Rapid and Complete Reversal of Sensory Ataxia by Gene Therapy in a Novel  
5 Model of Friedreich Ataxia. *Mol Ther.* May 2018.  
6 doi:10.1016/j.ymthe.2018.05.006
- 7 7. Bourguignon M, Jousmäki V, Op de Beeck M, Van Bogaert P, Goldman S, De  
8 Tiège X. Neuronal network coherent with hand kinematics during fast  
9 repetitive hand movements. *Neuroimage.* 2012;59(2):1684-1691.  
10 doi:10.1016/j.neuroimage.2011.09.022
- 11 8. Piitulainen H, Bourguignon M, De Tiège X, Hari R, Jousmäki V. Coherence  
12 between magnetoencephalography and hand-action-related acceleration, force,  
13 pressure, and electromyogram. *Neuroimage.* 2013;72:83-90.  
14 doi:10.1016/j.neuroimage.2013.01.029
- 15 9. Bourguignon M, Piitulainen H, De Tiège X, Jousmäki V, Hari R.  
16 Corticokinematic coherence mainly reflects movement-induced proprioceptive  
17 feedback. *Neuroimage.* 2015;106:382-390.  
18 doi:10.1016/j.neuroimage.2014.11.026
- 19 10. Piitulainen H, Bourguignon M, De Tiège X, Hari R, Jousmäki V.  
20 Corticokinematic coherence during active and passive finger movements.  
21 *Neuroscience.* 2013;238:361-370. doi:10.1016/j.neuroscience.2013.02.002
- 22 11. Piitulainen H, Bourguignon M, Hari R, Jousmäki V. MEG-compatible  
23 pneumatic stimulator to elicit passive finger and toe movements. *Neuroimage.*  
24 2015;112:310-317. doi:10.1016/j.neuroimage.2015.03.006
- 25 12. Marty B, Bourguignon M, Op de Beeck M, et al. Effect of movement rate on

- 1 corticokinematic coherence. *Neurophysiol Clin Neurophysiol*. 2015;45(6):469-  
2 474. doi:10.1016/j.neucli.2015.09.002
- 3 13. Santoro L, Perretti A, Lanzillo B, et al. Influence of GAA expansion size and  
4 disease duration on central nervous system impairment in Friedreich's ataxia:  
5 contribution to the understanding of the pathophysiology of the disease. *Clin*  
6 *Neurophysiol*. 2000;111(6):1023-1030. doi:10.1016/s1388-2457(00)00290-x
- 7 14. Taulu S, Simola J, Kajola M. Applications of the signal space separation  
8 method. *Signal Process IEEE ....* 2005. doi:10.1109/TSP.2005.853302
- 9 15. Bortel R, Sovka P. Regularization Techniques in Realistic Laplacian  
10 Computation. *IEEE Trans Biomed Eng.* 2007.  
11 doi:10.1109/TBME.2007.893496
- 12 16. Halliday DM, Rosenberg JR, Amjad AM, Breeze P, Conway BA, Farmer SF.  
13 A framework for the analysis of mixed time series/point process data--theory  
14 and application to the study of physiological tremor, single motor unit  
15 discharges and electromyograms. *Prog Biophys Mol Biol*. 1995;64(2-3):237-  
16 278.
- 17 17. Marty B, Bourguignon M, Jousmäki V, et al. Cortical kinematic processing of  
18 executed and observed goal-directed hand actions. *Neuroimage*. 2015;119:221-  
19 228. doi:10.1016/j.neuroimage.2015.06.064
- 20 18. Nichols TE, Holmes AP. Nonparametric permutation tests for functional  
21 neuroimaging: A primer with examples. *Hum Brain Mapp*. 2002.  
22 doi:10.1002/hbm.1058
- 23 19. Piitulainen H, Illman M, Laaksonen K, Jousmäki V, Forss N. Reproducibility  
24 of corticokinematic coherence. *Neuroimage*. 2018;179:596-603.  
25 doi:10.1016/j.neuroimage.2018.06.078

- 1 20. Cruz-Martínez A, Palau F, Cruz-Martinez A, Palau F. Central motor  
2 conduction time by magnetic stimulation of the cortex and peripheral nerve  
3 conduction follow-up studies in Friedreich's ataxia. *Electroencephalogr Clin*  
4 *Neurophysiol.* 1997;105(6):458-461. doi:10.1016/s0924-980x(97)00047-7
- 5 21. Santiago-Perez S, Perez-Conde MC, Ugalde-Canitrot A, Lopez-Pajares MR. A  
6 neurophysiological study of the alterations to the central and peripheral  
7 nervous systems in Friedreich's ataxia. *Rev Neurol.* 2007;44(4):193-197.
- 8 22. Santoro L, De Michele G, Perretti A, et al. Relation between trinucleotide  
9 GAA repeat length and sensory neuropathy in Friedreich's ataxia. *J Neurol*  
10 *Neurosurg Psychiatry.* 1999;66(1):93-96. doi:10.1136/jnnp.66.1.93
- 11 23. Vanasse M, Garcia-Larrea L, Neuschwander P, Trouillas P, Mauguière F.  
12 Evoked Potential Studies in Friedreich's Ataxia and Progressive Early Onset  
13 Cerebellar Ataxia. *Can J Neurol Sci / J Can des Sci Neurol.* 1988;15(03):292-  
14 298. doi:10.1017/s0317167100027773
- 15 24. Ouvrier RA, McLeod JG, Conchin TE. Friedreich's ataxia. Early detection and  
16 progression of peripheral nerve abnormalities. *J Neurol Sci.* 1982;55(2):137-  
17 145.
- 18 25. Pelosi L, Fels A, Petrillo A, et al. Friedreich's ataxia: clinical involvement and  
19 evoked potentials. *Acta Neurol Scand.* 1984;70(5):360-368.  
20 doi:10.1111/j.1600-0404.1984.tb00837.x
- 21 26. Jones SJ, Baraitser M, Halliday AM. Peripheral and central somatosensory  
22 nerve conduction defects in Friedreich's ataxia. *J Neurol Neurosurg Psychiatry.*  
23 1980;43(6):495-503. doi:10.1136/jnnp.43.6.495
- 24 27. Santoro L, Perretti A, Crisci C, et al. Electrophysiological and histological  
25 follow-up study in 15 Friedreich's ataxia patients. *Muscle Nerve.*



- 1 1990;13(6):536-540. doi:10.1002/mus.880130610
- 2 28. Cossée M, Dürr A, Schmitt M, et al. Friedreich's ataxia: point mutations and  
3 clinical presentation of compound heterozygotes. *Ann Neurol.* 1999;45(2):200-  
4 206. <http://www.ncbi.nlm.nih.gov/pubmed/9989622>. Accessed January 3,  
5 2019.
- 6 29. Ganes T. Somatosensory evoked responses and central afferent conduction  
7 times in patients with multiple sclerosis. *J Neurol Neurosurg Psychiatry.*  
8 1980;43(10):948-953.
- 9 30. Zegers de Beyl D, Delecluse F, Verbanck P, Borenstein S, Capel P, Brunko E.  
10 Somatosensory conduction in vitamin B12 deficiency. *Electroencephalogr Clin*  
11 *Neurophysiol.* 1988;69(4):313-318.
- 12 31. Tinazzi M, Manguiere F. Assessment of intraspinal and intracranial conduction  
13 by P30 and P39 tibial nerve somatosensory evoked potentials in cervical cord,  
14 brainstem, and hemispheric lesions. *J Clin Neurophysiol.* 1995;12(3):237-253.
- 15 32. Miyoshi T, Kimura J. Short-latency somatosensory evoked potentials in  
16 patients with cervical compressive lesions: morphological versus functional  
17 examination. *Electromyogr Clin Neurophysiol.* 1996;36(6):323-332.
- 18 33. Schmitz-Hubsch T, du Montcel ST, Baliko L, et al. Scale for the assessment  
19 and rating of ataxia: Development of a new clinical scale. *Neurology.*  
20 2006;66(11):1717-1720. doi:10.1212/01.wnl.0000219042.60538.92
- 21 34. van de Warrenburg BPC, Hendriks H, Dürr A, et al. Age at onset variance  
22 analysis in spinocerebellar ataxias: A study in a Dutch-French cohort. *Ann*  
23 *Neurol.* 2005;57(4):505-512. doi:10.1002/ana.20424
- 24 35. Reetz K, Dogan I, Costa AS, et al. Biological and clinical characteristics of the  
25 European Friedreich's Ataxia Consortium for Translational Studies (EFACTS)

- 1 cohort: a cross-sectional analysis of baseline data. *Lancet Neurol.*  
2 2015;14(2):174-182. doi:10.1016/S1474-4422(14)70321-7
- 3 36. Maas RPPWM, van Gaalen J, Klockgether T, van de Warrenburg BPC. The  
4 preclinical stage of spinocerebellar ataxias. *Neurology.* 2015;85(1):96-103.  
5 doi:10.1212/WNL.0000000000001711  
6  
7

1 **Legends of the figures**

2 **Figure 1**

3 Movement conditions. **Top.** *Passive* condition. Illustration of the passive movements  
4 of the right index finger induced by the Pneumatic Artificial Muscle (PAM)  
5 stimulator. During the experiments, the right index finger was taped to the moving  
6 extremity of the PAM stimulator. **Bottom.** One movement cycle of the right index  
7 finger and thumb in *Active* condition. An accelerometer was attached to the right  
8 index finger nail in both conditions.

9

10 **Figure 2**

11 Individual coherence spectra for each participant and movement condition (**Top,**  
12 *Active*; **Bottom,** *Passive*). Each gray trace represents the coherence between MEG  
13 and accelerometer signals for a single individual. For each frequency bin, the  
14 coherence value displayed is the maximum coherence across the MEG sensors  
15 covering the left rolandic MEG sensors. Black traces are group averages. Frequencies  
16 are expressed in F0 units (i.e., 1 corresponds to the individual F0, 2 to its F1, etc.).

17

18 **Figure 3**

19 Group-level coherence maps superimposed on brain surface rendering. All maps are  
20 thresholded at statistically significant coherence level (lower bound of the color scale,  
21 permutation-based statistics). The brain is viewed from the top. Group-level  
22 coherence maps for healthy controls (**Top**) and FRDA patients (**Middle**) in *Active*  
23 (**Left**) and *Passive* (**Right**) conditions at movement frequency (F0) and its first  
24 harmonics (F1). **Bottom.** Difference in group-level coherence maps between healthy  
25 controls and FRDA patients in *Active* (**Left**) and *Passive* (**Right**) conditions at F0 and

1 F1.

2

3 **Figure 4**


4 Plot of the Spearman correlation between FRDA patients' individual CKC levels at  
5 F1 in the *Active* condition and the size of GAA1 triplet expansion on the shortest  
6 allele (nGAA1) (**Left**) or the age of onset (**Middle**), and between FRDA patients'  
7 individual CKC levels at F1 in the *Passive* condition and the size of GAA1 triplet  
8 expansion on the shortest allele (nGAA1) (**Right**). Of note, when the two patients  
9 with the shortest GAA1 who are associated with the highest CKC values at F1 are  
10 removed from the analyses, correlations remain (nGAA1, *Active*:  $r = -0.66/p = 0.014$ ,  
11 *Passive*:  $r = -0.56/p = 0.047$ ; age of onset, *Active*:  $r = 0.56/p = 0.047$ )

12


13 **Table 1: Maximal coherence level at rolandic MEG sensors contralateral to**  
14 **finger movements**

	Maximal coherence level (mean $\pm$ SD)			
	<i>Active</i>		<i>Passive</i>	
	F0	F1	F0	F1
Healthy controls	0.39 $\pm$ 0.18	0.40 $\pm$ 0.18	0.32 $\pm$ 0.18	0.13 $\pm$ 0.08
FRDA patients	0.12 $\pm$ 0.08	0.11 $\pm$ 0.12	0.14 $\pm$ 0.14	0.06 $\pm$ 0.08

15




*Passive*




*Active*



Healthy subjects



FRDA patients



Passive



*Active*

*Passive*

F0

F1

F0

F1


Healthy controls




FRDA patients



Difference



### Active CKC level (F1)



### Passive CKC level (F1)

